Category: ~$230M

  • Hologic to Acquire Biotheranostics for ~$230M

    Shots: Hologic acquires Biotheranostics to speed up its entry in the oncology market. The transaction is expected to be completed in Feb’2021 The acquisition will provide Hologic access to Biotheranostics’ CLIA lab and will aid in accelerating market development for novel tests The acquisition allows Hologic to leverage commercial capabilities and expertise in molecular diagnostics […]